Violation Tracker Individual Record
Company:
Mylan Laboratories et al.
Current Parent Company:
Viatris
Penalty:
$108,000,000
Year:
2000
Date:
November 29, 2000
Offense Group:
competition-related offenses
Primary Offense:
price-fixing or anti-competitive practices
Violation Description:
Mylan paid $100 million (plus $8 million in legal fees) to settle a price-fixing case alleging that it developed a plan to drastically increase prices on two of its generic drugs by cutting off its competitors' supply of the drugs' active ingredients. Mylan accomplished this by entering into long-term profit-sharing agreements with industry suppliers and distributors that gave Mylan the only reliable sources of the active ingredients. The three other defendants -- which apparently were not required to share in the settlement costs -- were New Jersey-based Cambrex Corporation, Italian pharmaceutical ingredient manufacturer Profarmaco S.r.l. (a subsidiary of Cambrex), and New York-based drug distributor Gyma. The settlement was also announced by the Federal Trade Commission (see separate entry).
Level of Government:
state
Action Type:
agency action
Agency:
Multistate Attorneys General Case
Court:
District of the District of Columbia
Civil or Criminal Case:
civil
Case ID:
1:98-cv-3115
Case Name:
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation)
HQ Country of Parent:
USA
HQ State of Parent:
Pennsylvania
Ownership Structure of Parent:
publicly traded
Major Industry of Parent:
pharmaceuticals
Specific Industry of Parent:
pharmaceuticals
Link to PACER Case Docket (must be logged in):
Link to Archived Court Document:
Source Notes:
If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Parent company note:
Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.
